395 results on '"Piccart, M."'
Search Results
2. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0
3. SA 8.3 Emerging new treatments in HER2 positive breast cancer
4. Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit
5. LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
6. 230P Early metabolic response by FDG-PET scan predicts survival in patients with metastatic breast cancer receiving CDK4/6 inhibitors: Preliminary results from the PUCCINI study
7. 139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial
8. VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up
9. 69P Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial
10. 98P Neo-CheckRay, radiation therapy and adenosine pathway blockade to potentiate benefit of immuno-chemotherapy in early stage luminal B breast cancer: Results of the safety run-in phase
11. “The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores
12. Outcome without any adjuvant systemic treatment in stage I ER+/HER2− breast cancer patients included in the MINDACT trial
13. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
14. 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
15. 266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
16. 131P Impact of body mass (BMI) and weight change after adjuvant treatment in patients (pts) with HER2-positive early breast cancer
17. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
18. 72TiP ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast
19. Genomic tests for selecting therapy in adjuvant treatment of ER+ breast cancer (BC)
20. Immunotherapy for early breast cancer: too soon, too superficial, or just right?
21. Flexible care in breast cancer
22. 41P Cardiotoxicity of immune checkpoint inhibitors: A meta-analysis of randomized clinical trials
23. 84TiP Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer: A randomized phase II trial
24. 319O The systemic pro-inflammatory response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection
25. Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial
26. Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer
27. Corrigendum to “Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials”
28. 347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)
29. 221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO
30. LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
31. 170P β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial
32. 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
33. Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want
34. The legacy of Professor Aron Goldhirsch
35. 153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials
36. 188P Impact of HIV infection (HIV+) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis
37. 148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO)
38. 67P Digital analysis of distant and cancer-associated adipocytes in breast cancer
39. Male Breast Cancer
40. The EORTC-Breast Cancer Cooperative Group Clinical Research Programme in Early Breast Cancer
41. Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer
42. SERIOUS ADVERSE EVENTS AMONG OLDER PATIENTS IN THE ALTTO TRIAL
43. PCN457 THE SISAQOL INITIATIVE: ESTABLISHING INTERNATIONAL STANDARDS AND RECOMMENDATIONS FOR THE ANALYSIS OF PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE DATA IN ONCOLOGY RANDOMIZED CLINICAL TRIALS
44. ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer
45. Corrections to “PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab”
46. Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial
47. Immune functions of follicular helper CD4+CXCR5+ T cells in human breast cancer
48. SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
49. First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)
50. News in systemic therapy of patients with early BC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.